Cargando…

The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal Carcinoma: The Dawn of a New Era? A Systematic Review and Meta-Analysis of 7836 Cases: Erratum

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2015
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616494/ http://dx.doi.org/10.1097/01.md.0000471511.15485.81

Ejemplares similares

The Clinical Utility of Plasma Epstein–Barr Virus DNA Assays in Nasopharyngeal Carcinoma: The Dawn of a New Era?: A Systematic Review and Meta-Analysis of 7836 Cases
por: Zhang, Wenna, et al.
Publicado: (2015)

Erratum to: Molecular Detection of Epstein - Barr virus in Nasopharyngeal Carcinoma among Sudanese population
por: Edris, Ali, et al.
Publicado: (2016)

Erratum for Caves et al., “Air-Liquid Interface Method To Study Epstein-Barr Virus Pathogenesis in Nasopharyngeal Epithelial Cells”
por: Caves, Elizabeth A., et al.
Publicado: (2019)

Erratum to: Brave new epigenomes: the dawn of epigenetic engineering
por: Köferle, Anna, et al.
Publicado: (2015)

Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma
por: Chan, K.C. Allen
Publicado: (2014)

Plasma Epstein-Barr viral DNA complements TNM classification of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy
por: Zhang, Lu, et al.
Publicado: (2015)

Prevalence and significance of plasma Epstein-Barr Virus DNA level in nasopharyngeal carcinoma
por: Prayongrat, Anussara, et al.
Publicado: (2017)

Clinical value of a plasma Epstein–Barr virus DNA assay in the diagnosis of recurrent or metastatic nasopharyngeal carcinoma: a meta-analysis
por: Peng, Haiqin, et al.
Publicado: (2019)

Erratum for Murer et al., “MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control In Vivo”
por: Murer, Anita, et al.
Publicado: (2019)

Epstein–Barr virus and multiple sclerosis: the dawn of a new age
por: Phan, Tri Giang
Publicado: (2023)

Epstein–Barr Virus-Positive T/NK-Cell Lymphoproliferative Disorders Manifested as Gastrointestinal Perforations and Skin Lesions: A Case Report: Erratum
Publicado: (2016)

Clinical utility of Epstein‐Barr virus DNA and other liquid biopsy markers in nasopharyngeal carcinoma
por: Tan, Rong, et al.
Publicado: (2020)

Epstein-Barr virus and carcinomas: rare association of the virus with gastric adenocarcinomas
por: Rowlands, D C, et al.
Publicado: (2016)

Defective T-cell control of Epstein–Barr virus infection in multiple sclerosis
por: Pender, Michael P, et al.
Publicado: (2017)

Epstein-Barr virus and nasopharyngeal carcinoma
por: Young, Lawrence S., et al.
Publicado: (2014)

The impact of plasma epstein–barr virus DNA and fibrinogen on nasopharyngeal carcinoma prognosis: an observational study
por: Tang, L-Q, et al.
Publicado: (2014)

Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population
por: Chen, Wen-Jie, et al.
Publicado: (2021)

Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy: Erratum
por: Hu, Jianmin, et al.
Publicado: (2022)

Impact of Plasma Epstein-Barr Virus-DNA and Tumor Volume on Prognosis of Locally Advanced Nasopharyngeal Carcinoma
por: Chen, Meng, et al.
Publicado: (2015)

Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma
por: Zhang, Jian, et al.
Publicado: (2018)

Prognostic value of Epstein-Barr virus DNA load in nasopharyngeal carcinoma: a meta-analysis
por: Alami, Imane EL, et al.
Publicado: (2022)

Validation of a Highly Sensitive qPCR Assay for the Detection of Plasma Cell-Free Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma Diagnosis
por: Anh, Vu Nguyen Quynh, et al.
Publicado: (2020)

Prognostic value of serum Epstein–Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein–Barr virus DNA
por: Yao, Ji‐Jin, et al.
Publicado: (2017)

Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
por: Hau, Pok Man, et al.
Publicado: (2020)

The role of Epstein–Barr virus in nasopharyngeal carcinoma
por: Su, Zhi Yi, et al.
Publicado: (2023)

Positivity of both plasma Epstein–Barr virus DNA and serum Epstein–Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma
por: Zhao, Fei-Peng, et al.
Publicado: (2014)

Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinoma
por: Zhang, Yuan, et al.
Publicado: (2016)

Corrigendum to “Validation of a Highly Sensitive qPCR Assay for the Detection of Plasma Cell-Free Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma Diagnosis”
Publicado: (2020)

Evaluation of plasma Epstein–Barr virus DNA as a biomarker for Epstein–Barr virus–associated Hodgkin lymphoma
por: Usha, Masuma Khatun, et al.
Publicado: (2021)

The evolution of Epstein-Barr virus detection in nasopharyngeal carcinoma
por: Li, You Quan, et al.
Publicado: (2018)

Role of Epstein-Barr Virus in the Development of Nasopharyngeal Carcinoma
por: Zhang, Hui, et al.
Publicado: (2017)

Detecting plasma Epstein-Barr virus DNA to diagnose postradiation nasopharyngeal skull base lesions in nasopharyngeal carcinoma patients: a prospective study
por: Liang, Fa-Ya, et al.
Publicado: (2012)

Erratum to “The utility of cfDNA in TGCT patient management: a systematic review”
Publicado: (2022)

Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma
por: Lam, W. K. Jacky, et al.
Publicado: (2018)

Relationship between pretreatment concentration of plasma Epstein‐Barr virus DNA and tumor burden in nasopharyngeal carcinoma: An updated interpretation
por: Peng, Liang, et al.
Publicado: (2018)

Clinical characteristics and prognostic value of pre‐retreatment plasma epstein‐barr virus DNA in locoregional recurrent nasopharyngeal carcinoma
por: Liu, Ming‐Zhu, et al.
Publicado: (2019)

Integrating pre- and post-treatment Plasma Epstein-Barr Virus DNA levels for better prognostic prediction of Nasopharyngeal Carcinoma
por: Li, Wanxia, et al.
Publicado: (2021)

Prognostic Value of Plasma Epstein-Barr Virus DNA Levels Pre- and Post-Neoadjuvant Chemotherapy in Patients With Nasopharyngeal Carcinoma
por: Zhu, Lisheng, et al.
Publicado: (2021)

Prognostic effect of residual plasma Epstein–Barr viral DNA after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma
por: Zheng, Hua, et al.
Publicado: (2023)

Prognostic Value of Plasma Epstein–Barr Virus DNA for Local and Regionally Advanced Nasopharyngeal Carcinoma Treated With Cisplatin-Based Concurrent Chemoradiotherapy in Intensity-Modulated Radiotherapy Era
por: Chen, Wen-Hui, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_qf3qnoo8unugog6hiaomkslv49